'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial.
Amr S GamalHironori HaraMariusz TomaniakMattia LunardiChao GaoMasafumi OnoHideyuki KawashimaPeter JüniPascal VranckxStephan WindeckerChristian HammPhilippe Gabriel StegYoshinobu OnumaPatrick W SerruysPublished in: European heart journal. Acute cardiovascular care (2021)
Presentation with STEMI has not influenced the incidence of GLOBAL LEADERS defined primary endpoints. There were no significant differences in rates of NACE, POCE, and BARC bleeding between the two treatment groups up to 2 years of follow-up. Although these findings should be viewed as exploratory, they expand the evidence on potential safety of aspirin-free antiplatelet strategies after PCI in STEMI.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- coronary artery disease
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- phase iii
- coronary artery bypass grafting
- atrial fibrillation
- phase ii
- open label
- double blind
- coronary artery bypass
- clinical trial
- coronary artery
- cardiovascular events
- study protocol
- risk factors
- randomized controlled trial
- cardiovascular disease
- placebo controlled
- type diabetes
- case report
- low dose
- combination therapy
- heart failure